In a report published Thursday, Stifel Nicolaus analyst
Rick Wise reiterated a Buy rating on Boston Scientific Corporation (NYSE: BSX), and raised the price target from $9.00 to $11.00.In the report,
Wise noted, “While BSX shares are up 78% in the last ...
[Published Benzinga.com - May 16 2013]